prescription corticosteroids

Alberto Zucchelli, Davide L Vetrano, Elisa Bianchini, Francesco Paolo Lombardo, Alessio Piraino, Marco Zibellini, Alberto Ricci, Alessandra Marengoni, Francesco Lapi, Claudio Cricelli
INTRODUCTION: The development of new pharmacological treatments for chronic obstructive pulmonary disease (COPD) has improved health-related quality of life of patients. However, suboptimal adherence may limit its potential. OBJECTIVE: The aim of the present study was to assess the adherence to free triple inhaled therapy and to investigate poor adherence determinants among primary care patients. METHODS: Data were derived from a primary care database in Italy...
March 26, 2020: Clinical Respiratory Journal
Yuh-Lih Chang, Hsin-Kuo Ko, Meng-Shui Lu, Chia-Lin Chou, Kang-Cheng Su, Chia-Chen Hsu, Kun-Ta Chou, Tzeng-Ji Chen, Diahn-Warng Perng, Yueh-Ching Chou
The independent risk factors for death in patients admitted for asthma exacerbation have not been thoroughly investigated. This study aimed to investigate these independent risk factors and the relationship between mortality and the prescription patterns of anti-asthmatic medications in patients admitted for asthma exacerbation. Using a nested case-control design, we identified 267 cases (death after asthma admission) and 1035 controls (survival after asthma admission) from the Taiwan National Health Insurance Research Database (NHIRD) from 2001 to 2010...
March 19, 2020: NPJ Primary Care Respiratory Medicine
Giorgio Ciprandi, Salvatore Leonardi, Anna Maria Zicari, Maria Angela Tosca, Gianluigi Marseglia
Allergic rhinoconjunctivitis (AR) is the most common IgE-mediated disease. A type2 immune response is involved in AR pathogenesis. Allergic inflammation is characterized by eosinophilic infiltrate and mediators release. AR treatment is usually based on medication prescription, including antihistamines and intranasal corticosteroids. However, medications may be prescribed for long periods and sometimes may be scarcely effective, thus aggressive strategy should be used. Therefore, complementary medicine is becoming attractive for patients at present...
March 19, 2020: Acta Bio-medica: Atenei Parmensis
Qingqing Xu, Sarah S Laxa, Omar Serna, Sujit S Sansgiry
Background: Several medications, including long-acting bronchodilators (LABDs), are critical to the management of chronic obstructive pulmonary disease (COPD). Clinical guidelines recommend the initiation of an LABD for COPD posthospitalization to prevent exacerbations. COPD can limit a patient's exercise tolerance, mobility, and ability to work. Disease exacerbations resulting from inadequate treatment have contributed to increased medical costs and morbidity. Objectives: To analyze the prescription fills for COPD medications, especially LABDs, before and after COPD-related hospitalization, in elderly patients, and to evaluate factors associated with prescription fills of LABDs after COPD-related hospitalization...
February 2020: American Health & Drug Benefits
Trung N Tran, Elizabeth King, Rajiv Sarkar, Cassandra Nan, Annalisa Rubino, Caroline O'Leary, Ruvimbo Muzwidzwa, Laura Belton, Jennifer K Quint
Oral corticosteroids (OCS) are used to manage asthma exacerbations and severe, uncontrolled asthma, but OCS use is associated with adverse effects. We aimed to describe the patterns of OCS use in the real-world management of patients with asthma in western Europe.We used electronic medical records from databases in France, Germany, Italy, and the United Kingdom from July 2011 through February 2018. Patients aged ≥12 years with an asthma diagnosis, ≥1 non-OCS asthma medication within ±6 months of diagnosis, and available data ≥6 months prior to and ≥90 days after cohort entry were included...
March 12, 2020: European Respiratory Journal
P Kardos, F Geiss, J Simon, C Franken, U Butt, H Worth
INTRODUCTION:  Inhalative treatments with metered dose aerosols and dry powder inhalers are the backbone of the pharmacotherapy for asthma and COPD. In the last decade many new and generic inhalative bronchodilators were launched at the German market, both monotherapies and fixed dose double bronchodilator (LABA/LAMA, beta adrenergic and antimuscarinic) or LABA and inhaled corticosteroid (ICS) and triple (LABA/LAMA/ICS) combinations. According to two surveys in 2015 among respiratory physicians we expected a high proportion of patients receiving duplicate prescriptions, e...
March 2020: Pneumologie
Marjolein Engelkes, Esme J Baan, Maria A J de Ridder, Elisabeth Svensson, Daniel Prieto-Alhambra, Francesco Lapi, Carlo Giaquinto, Gino Picelli, Nada Boudiaf, Frank Albers, Lee A Evitt, Sarah Cockle, Eric Bradford, Melissa K Van Dyke, Robert Suruki, Peter Rijnbeek, Miriam C J M Sturkenboom, Hettie M Janssens, Katia M C Verhamme
BACKGROUND: There are sparse real world data on severe asthma exacerbations (SAE) in children. This multinational cohort study assessed the incidence and risk factors of SAE and the incidence of asthma related rehospitalization in asthmatic children. METHODS: Asthma patients 5-17 years with ≥1 year of follow-up were identified in six European electronic databases from the Netherlands, Italy, UK, Denmark and Spain in 2008-2013. Asthma was defined as ≥1 asthma specific disease code within 3 months of prescriptions/dispensing of asthma medication...
March 1, 2020: Pediatric Allergy and Immunology
A Rouland, P Buffier, J-M Petit, B Vergès, B Bouillet
Thyroiditis is a frequent and mostly benign disease that can sometimes disrupt the thyroid balance. Their diagnosis, as well as their aetiology, is a necessary step in the management of the patients. Painful thyroiditis includes acute thyroiditis of infectious origin and subacute thyroiditis. The first one can be treated by antibiotics or antifungals depending on the germ found. The second one will be treated with non-steroidal anti-inflammatory drugs or corticosteroids. In cases of Hashimoto's thyroiditis with overt hypothyroidism, replacement therapy with L-thyroxine will be adapted to the TSH level...
February 24, 2020: La Revue de Médecine Interne
Katrina Wilcox Hagberg, Rebecca Persson, Catherine Vasilakis-Scaramozza, Steve Niemcryk, Michael Peng, Maria Paris, Anders Lindholm, Susan Jick
Purpose: Psoriasis and psoriatic arthritis (PsA) are associated with an increased infection risk. In this cohort study of patients with treated psoriasis or PsA, we used MarketScan (2014-2018) to estimate rates of herpes zoster, hepatitis C (HepC) and tuberculosis (TB) with apremilast compared to other systemic treatments. Materials and Methods: Patients were exposed from first apremilast [APR], DMARD, TNF-inhibitor [TNF], IL-inhibitor [IL], or corticosteroids [CS] prescription after March 21, 2014...
2020: Clinical Epidemiology
Hasse Melbye, Jon Helgeland, Øystein Karlstad, Inger Ariansen, Arnulf Langhammer, Torbjørn Wisløff, Per Nafstad, Wenche Nystad
Background: Less smoking should lead to fewer COPD cases. We aimed at estimating time trends in the prevalence and burden of COPD in Norway from 2001 to 2017. Methods: We used pre-bronchodilator spirometry and other health data from persons aged 40-84 years in three surveys of the Tromsø Study, 2001-2002, 2007-2008 and 2015-2016. We applied spirometry lower limits of normal (LLN) according to Global Lung Initiative 2012. Age-standardized prevalence was determined...
2020: International Journal of Chronic Obstructive Pulmonary Disease
Silvia Calabria, Giulia Ronconi, Letizia Dondi, Carlo Piccinni, Antonella Pedrini, Immacolata Esposito, Riccardo Pistelli, Nello Martini
BACKGROUND: The combination of two long acting bronchodilators with an inhaled corticosteroid, known as Triple Therapy (TT), is a usual clinical practice for patients affected by chronic obstructive pulmonary disease (COPD). This analysis aimed to identify subjects with COPD treated with extemporaneous combination of ICS/LABA and LAMA (namely open TT) and to describe the pharmacological strategy, the spirometry use, the exacerbations occurrence and the costs, in the perspective of the Italian National Health System (NHS)...
February 21, 2020: Pulmonary Pharmacology & Therapeutics
John Mackowiak, John T Jones, Vinod Dasa
OBJECTIVES: To compare the medical costs associated with treatments for knee osteoarthritis (OA): intra-articular corticosteroids (ICS) and intra-articular hyaluronic acid (IHA) primarily, and ICS/IHA vs knee arthroplasty (TKA) secondarily. METHODS: This was a retrospective analysis of an insurance claims database. Eligible members had diagnosed OA and no claims for ICS, IHA, or TKA during the 6-18-month look-back period. Cohorts of interest over the 4-year observation period were: patients who received ICS only, those who received IHA only, and those who received TKA only...
January 17, 2020: Seminars in Arthritis and Rheumatism
Aida Moure-Fernandez, Sandra Hollinghurst, Fran E Carroll, Harriet Downing, Grace Young, Sara Brookes, Margaret May, Magdy El-Gohary, Anthony Harnden, Denise Kendrick, Natasher Lafond, Paul Little, Michael Moore, Elizabeth Orton, Matthew Thompson, David Timmins, Kay Wang, Alastair D Hay
OBJECTIVE: To estimate the costs and outcomes associated with treating non-asthmatic adults (nor suffering from other lung-disease) presenting to primary care with acute lower respiratory tract infection (ALRTI) with oral corticosteroids compared with placebo. DESIGN: Cost-consequence analysis alongside a randomised controlled trial. Perspectives included the healthcare provider, patients and productivity losses associated with time off work. SETTING: Fifty-four National Health Service (NHS) general practices in England...
February 18, 2020: BMJ Open
Valérie Johnson Girard, Ashley Hill, Emma Glaser, Marie-Thérèse Lussier
BACKGROUND: Patients are often non-adherent to topical corticosteroids (TCS). This may be in part due to poor communication between patients and dermatologists. OBJECTIVES: This quality improvement (QI) study aims to describe dermatologist-patient communication about TCS treatments and to compare communication before and after the implementation of an educational intervention. METHODS: This QI study assesses the communication between dermatologists and new dermatology outpatients receiving a TCS prescription in a tertiary care center...
February 19, 2020: Journal of Cutaneous Medicine and Surgery
Svanhildur Haflidadottir, Iren Lindbak Matthews, Runar Almaas
BACKGROUND: LTX in children is associated with increased risk of food allergy, and the mechanisms underlying this are unknown. We wanted to study whether plasma cytokine profile differed in liver transplanted children, with and without food allergy, and whether it differed from untransplanted children with CLD. METHODS: Plasma cytokines, total and specific IgE in nine patients with food allergy were compared with 13 patients without food allergy following LTX, and also with seven untransplanted patients with CLD...
March 2020: Pediatric Transplantation
Gráinne d'Ancona, Joanne Kavanagh, Cris Roxas, Linda Green, Mariana Fernandes, Louise Thomson, Jaideep Dhariwal, Alexandra M Nanzer, David J Jackson, Brian D Kent
INTRODUCTION: Inhaled corticosteroids (ICS) achieve disease control in the majority of asthmatics, although adherence to prescribed ICS is often poor. Patients with severe eosinophilic asthma (SEA) may require treatment with oral corticosteroids (OCS) and/or biologic agents such as mepolizumab. It is unknown if ICS adherence changes on, or alters clinical response to, biologic therapy. METHODS: We examined ICS adherence and clinical outcomes in OCS-dependent SEA patients who completed 1 year of mepolizumab therapy...
February 14, 2020: European Respiratory Journal
Michael C Kwa, Kyle Tegtmeyer, Leah J Welty, Sam G Raney, Markham C Luke, Shuai Xu, Betty Kong
The cost of prescription drugs has increased at rates far exceeding general inflation in recent history, with topical drugs increasing at a disproportionate rate compared to other routes of administration. We assessed the relationship between net changes in the number of therapeutic options, defined as any approved drug or therapeutic equivalent on the market, and prescription topical drug spending. Drugs were divided based on the category of use through pairing of Medicare Part D Prescriber Public Use and Food and Drug Administration (FDA) approved drug products databases...
February 13, 2020: Archives of Dermatological Research
Christos V Chalitsios, Dominick E Shaw, Tricia M McKeever
Exposure to oral corticosteroids (OCS) is associated with an increased risk of osteoporosis and fragility fractures. Guidelines suggest bisphosphonate (BP) therapy as the first-line treatment of glucocorticoid-induced osteoporosis (GIOP). This population study used publicly available data, including prescription annual cost analysis and monthly practice-level data. Our aim was to examine the prescribing of OCS and BP at practice level and investigate reasons for variation using a mixed-effect negative binomial regression analysis...
February 13, 2020: NPJ Primary Care Respiratory Medicine
Taisuke Jo, Hideo Yasunaga, Yasuhiro Yamauchi, Akihisa Mitani, Yoshihisa Hiraishi, Wakae Hasegawa, Yukiyo Sakamoto, Hiroki Matsui, Kiyohide Fushimi, Takahide Nagase
Background: Inhaled corticosteroids (ICSs) are used for advanced-stage chronic obstructive pulmonary disease (COPD). The application and safety of ICS withdrawal remain controversial.This study aimed to evaluate the association between ICS withdrawal and outcomes in elderly patients with COPD with or without comorbid bronchial asthma, who were hospitalised for exacerbation. Patients and methods: We conducted a retrospective cohort study using the Japanese Diagnosis Procedure Combination database from July 2010 to March 2016 ...
January 2020: ERJ Open Research
Daniel Dedman, Sonia J Coton, Rebecca E Ghosh, Wilhelmine Meeraus, Courtney Crim, Catherine Harvey, Justyna Amelio, Sarah H Landis
INTRODUCTION: This retrospective database study explored treatment patterns and potential off-label prescribing among patients newly prescribed fluticasone furoate/vilanterol (FF/VI) in a UK primary care setting. METHODS: In Europe, FF/VI is approved in two strengths: 100/25 µg for adults with chronic obstructive pulmonary disease (COPD) and 100/25 µg or 200/25 µg for treatment of asthma in patients aged 12 or older. Using electronic health records from the Clinical Practice Research Datalink, new users of FF/VI or other inhaled corticosteroid/long-acting beta-agonist fixed-dose combination products were identified and classified into one of three groups: COPD diagnosis, asthma diagnosis, and other diagnosis (not COPD or asthma)...
June 2019: Pulmonary Therapy
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"